CD44 and head and neck squamous cell carcinoma: Moreover, in CCL-138 and CCL-138-R cells, treatment with dasatinib (a major p-Src inhibitor) led to a reduction in the CD44 and Sox2 protein levels (Figure S9A) without affecting the SDCBP expression levels (data not shown), and it sensitized HNSCC cells to CDDP (Figure S9B).